Low Expression of Keratin17 is Related to Poor Prognosis in Bladder Cancer

Figures & data

Figure 1 (A) Low expression of KRT17 in cancer tissues (a, magnification, ×4; b, magnification, ×10; c, magnification, ×20; d, magnification, ×40). (B) High expression of KRT17 in cancer tissues (a, magnification, ×4; b, magnification, ×10; c, magnification, ×20; d, magnification, ×40). (C) Low expression of KRT17 in the adjacent tissues (a, magnification, ×4; b, magnification, ×10; c, magnification, ×20; d, magnification, ×40). (D) High expression of KRT17 in the adjacent tissues (a, magnification, ×4; b, magnification, ×10; c, magnification, ×20; d, magnification, ×40).

Figure 2 High mRNA expression level of KRT17 in tumor tissues in the online database GEPIA.

Note: *Was statistically significant.

Figure 3 High mRNA expression level of KRT17 in tumour tissues using qRT-PCR.

Table 1 The Relationship Between the Expression of KRT17 and Clinicopathological Data

Variables	Total	Low Expression	High Expression	p
	n (%)	n (%)	n (%)
Gender
Male	82 (81.2)	37 (45.1)	45 (54.9)	0.859
Female	19 (18.8)	9 (47.4)	10 (52.6)
Age (years)
≤65	39 (38.6)	19 (48.7)	20 (51.3)	0.55
>65	62 (61.4)	27 (43.5)	35 (56.5)
Recurrence
Yes	23 (22.8)	8 (34.8)	15 (65.2)	0.238
No	78 (77.2)	38 (48.7)	40 (51.3)
Number of tumors
Single	70 (69.3)	30 (42.9)	40 (57.1)	0.415
Multiple	31 (30.7)	16 (51.6)	15 (48.4)
Tumor size (cm)
≤5	76 (75.2)	30 (39.5)	46 (60.5)	0.033*
>5	25 (24.8)	16 (64.0)	9 (36.0)
Operation mode
Transurethral resection	50 (49.5)	18 (36.0)	32 (64.0)	0.057
Radical cystectomy	51 (50.5)	28 (54.9)	23 (45.1)
Adjuvant chemotherapy
Yes	54 (53.5)	22 (40.7)	32 (59.3)	0.299
No	47 (46.5)	24 (51.1)	23 (48.9)
Bladder triangle involvement
Yes	18 (17.8)	10 (55.6)	8 (44.4)	0.347
No	83 (82.2)	36 (43.4)	47 (56.6)
External invasion
Yes	13 (12.9)	8 (61.5)	5 (38.5)	0.215
No	88 (87.1)	38 (43.2)	50 (56.8)
Vascular tumor thrombus
Yes	13 (12.9)	7 (53.8)	6 (46.2)	0.520
No	88 (87.1)	39 (44.3)	49 (55.7)
T stage
T1	51 (50.5)	7 (13.7)	44 (86.3)	<0.0001*
T2+T3+T4	50 (49.5)	39 (78.0)	11 (22.0)
Grade
G1+G2	49 (48.5)	3 (6.1)	46 (93.9)	<0.0001*
G3	52 (51.5)	43 (82.7)	9 (17.3)
Lymph node metastasis
Yes	32 (31.7)	14 (43.8)	18 (56.2)	0.805
No	69 (68.3)	32 (46.4)	37 (53.6)
Other site metastasis
Yes	10 (9.9)	5 (50.0)	5 (50.0)	0.766
No	91 (90.1)	41 (45.1)	50 (54.9)

Note: *P < 0.05 was statistically significant.

Figure 4 (A) Kaplan–Meier analysis of overall survival (OS) in patients with bladder cancer. (B) Kaplan-Meier analysis of progression-free survival (PFS) in patients with bladder cancer.

Table 2 Univariate Analysis of Clinical Factors on 101 Patients with OS

Variables	HR	(95% CI)	p
Gender
Male	1.019	(0.344–3.021)	0.972
Female	1
Age (years)
≤65	1	(0.352–1.896)	0.638
>65	0.817
Recurrence
Yes	1.116	(0.414–3.009)	0.829
No	1
Number of tumors
Single	1	(0.169–1.473)	0.208
Multiple	0.498
Tumor size (cm)
≤5	3.342	(1.442–7.746)	0.005
>5	1
Operation mode
Transurethral resection	1.693	(0.704–4.075)	0.240
Radical cystectomy	1
Adjuvant chemotherapy
Yes	1.105	(0.475–2.573)	0.817
No	1
Bladder triangle involvement
Yes	2.105	(0.491–9.023)	0.316
No	1
External invasion
Yes	1	(0.229–2.027)	0.490
No	0.681
Vascular tumor thrombus
Yes	1	(0.135–0.885)	0.027
No	0.345
T stage
T1	50.404	(5.122–496.040)	0.001
T2+T3+T4	1
Grade
G1+G2	11.915	(3.34–42.504)	0.000
G3	1
Lymph node metastasis
Yes	1.054	(0.426–2.608)	0.909
No	1
Other site metastasis
Yes	1	(0.145–1.283)	0.131
No	0.431
Expression of KRT17
Low expression	1	(0.034–0.320)	0.000
High expression	0.105

Table 3 Multivariate Analysis of Clinical Factors in 101 Patients with OS

Variables	HR	(95% CI)	p
Tumor size (cm)
≤5	1	(0.16–0.904)	0.029
>5	0.380
Vascular tumor thrombus
Yes	3.138	(1.18–8.343)	0.022
No	1
T stage
T1	1	(0.001–0.400)	0.01
T2+T3+T4	0.022
Expression of KRT17
Low expression	4.263	(1.272–14.290)	0.019
High expression	1

Figure 5 Prediction model of nomogram construction.

Figure 6 The GSEA result showed the most relevant enrichment pathway.